Biotech

All Articles

A nearer check out Tough Biotech's Brutal 15

.In this week's episode of "The Best Pipe," our team are actually diving right into Strong Biotech's...

Lilly encounters period 2 failure of tau-targeting med

.The confetti is actually still soaring from Eli Lilly's party celebrating the commendation of Alzhe...

Biogen CMO Maha Radhakrishnan participates in Sofinnova-- Chutes &amp Ladders

.Accept to this week's Chutes &amp Ladders, our roundup of considerable leadership hirings, shooting...

Lykos will inquire FDA to reconsider its own decision observing rejection of MDMA treatment for trauma

.Adhering to an inadequate presenting for Lykos Rehabs' MDMA prospect for post-traumatic stress diso...

AN 2 halves census, quits stage 3 trial after information let down

.AN2 Therapeutics is reassessing its own company in feedback to lackluster midphase records, pledgin...

Merck pays for $700M for bispecific, spying autoimmune position and odds to test Amgen in cancer

.Merck &amp Co. is actually paying $700 million upfront to challenge Amgen in a blood cancer market....

Gilead pays for J&ampJ $320M to exit licensing package for seladelpar

.Along With Gilead Sciences on the verge of an FDA choice for its own liver ailment drug seladelpar,...

' All hands on deck' at Lilly as peers target being overweight market

.Chief executive officer David Ricks can see the providers putting together tents at basecamp respon...

Entero laying off workers, abandoning workplace and pausing R&ampD

.Bed mattress Liquidators has switched Entero Therapies white colored as a sheet. The lender ordered...

Exelixis loses ADC after determining it's no suit for Tivdak

.Exelixis is actually giving up on its tissue aspect (TF)- targeting antibody-drug conjugate after c...